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Background: Whether the single nucleotide polymorphism (SNP) Lys751Gln of xeroderma pigmentosum group D
(XPD) gene increases susceptibility to head and neck cancer (HNC) is controversial and undetermined. Therefore,
we conducted this meta-analysis to systematically assess the possible association between them.
Methods: The OVID, Medline, Embase, Pubmed, Web of Science databases were searched to identify the eligible
studies. The odds ratio (OR) with 95% confidence interval (95% CI) were used to assess the strength of association.
Results: A total of 11,443 subjects from eighteen studies were subjected to meta-analysis. Overall, XPD Lys751Gln
polymorphism had no association with increased HNC risk under all five genetic models (P > 0.05). In the subgroup
analysis by ethnicity and source of controls, still no significant association was found under five genetic models
(P > 0.05). In the subgroup analysis by cancer type, XPD Lys751Gln polymorphism had statistically significant association
with elevated laryngeal cancer (LC) and nasopharyngeal cancer (NPC) risk under heterozygous comparison and
dominant model (P<0.05) and borderline significantly increased risk was found under allele contrast for LC and NPC.
Carriers of Lys allele and Lys/Lys genotype may be associated with elevated LC and NPC risk.
Conclusions: There is overall lack of association between XPD Lys751Gln polymorphism and HNC risk under all five
genetic models and still no significant association was found in the subgroup analysis by ethnicity and source of
controls. However, XPD Lys751Gln polymorphism was significantly associated with susceptibility to LC and NPC and
the Lys allele and Lys/Lys genotype of XPD Lys751Gln polymorphism may be a risk factor for LC and NPC. However,
relatively modest sample sizes were included in this meta-analysis and studies with large sample sizes and representative
population are warranted to further clarify this finding.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
5628716106316015.
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Head and neck cancers (HNC) which involve malignant
neoplasms of the oral cavity, pharynx, and larynx, are the
sixth most common cancers threatening human life world-
wide [1]. To date, there are ample evidences indicating
that HNC is a complex multifactorial disorder involving
genetic factors, lifestyle, tobacco smoke, alcohol con-
suming, and environmental factors [2-6] and some low-* Correspondence: 96zheng@gmail.com
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reproduction in any medium, provided the orpenetrant genes have been identified as potential HNC
susceptibility genes [7-9]. Among them, an important one
is xeroderma pigmentosum group D(XPD) gene, which is
located on chromosome 19q13.3. XPD gene, also known
as excision repair cross-complementing group 2 (ERCC2)
gene, encodes XPD protein, one ATP-dependent helicase
within the multi subunit transcription repair factor com-
plex,TFIIH, participates in DNA unwinding during the
nucleotide excision repair (NER) pathway and plays a piv-
otal role in the recognition and repairment of structurally
unrelated DNA lesions including bulky adducts and thy-
midine dimmers [10-12]. Dysregulation of DNA repair. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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esis of cancers [13,14].
The XPD Lys751Gln polymorphism (A35931C, rs13181
or rs1052559) is caused by A to C transition at codon 751
in exon 23 of XPD gene resulting in the Gln substitution
for Lys. The XPD Lys751Gln polymorphism may lead to
reduction in helicase activity and DNA repair capacity and
may be important in the carcinogenesis and development
of HNC [15,16].
To date, a series of case–control studies have been
conducted to clarify the association between XPD
Lys751Gln polymorphism and HNC risk. However, the
results were inconsistent. Therefore, we performed this
meta-analysis in order to precisely assess the possible as-




The OVID, Medline, Embase,Pubmed, Web of Science
databases (up to July 2013) were searched to identify
the studies focusing on the association between XPD
Lys751Gln polymorphism and susceptibility to HNC.
The formats of search terms were used as follows: “xero-
derma pigmentosum group D”, “XPD”, “excision repair
cross-complementing group 2”, “ERCC2”, “head and neck
cancer”, “oral cancer”, “pharyngeal cancer”, “oropharyn-
geal cancer”, “nasopharyngeal cancer”, “laryngeal cancer”,
“SNP or polymorphism or variant” and the combination
of them. The literature retrieval was performed by two
authors (H. Lin and D. Lin) independently. Relevant re-
views and abstracts of meetings were searched for related
studies.
Inclusion and exclusion criteria
Eligible studies which satisfied the following inclusion
criteria would be included: 1) the study clearly assessed
the association between XPD Lys751Gln polymorphism
and HNC risk; 2) HNC was diagnosed by histopatho-
logical examination; 3) the normal healthy controls had
no diagnosis of HNC. On the other hand, the exclusion
criteria was used as follows: 1) studies without normal
healthy controls; 2) studies without essential data and in-
formation; 3) studies in which the genotype distributions
in the controls significantly deviated from Hardy–Wein-
berg equilibrium (HWE).
Data extraction
Two authors (H. Lin and D. Lin) performed the extrac-
tion of relevant data respectively from all eligible studies.
Disagreement was resolved by discussing between two
authors (H. Lin and D. Lin). The relevant data as listed
below were extracted: name of first author, publication
year, country, ethnicity, source of controls, genotypingmethod, cancer type, total number of cancer patients
and controls, and distribution of genotypes in these two
groups and P-value of HWE tested in controls. The
categorization of ethnicity comprised Caucasian and
Asian. Source of controls was categorized as population-
based study, hospital-based study, nested case–control
study and mixed study. The categorization of cancer
type involved laryngeal cancer, oral cancer and nasopha-
ryngeal cancer.
Statistical analysis
Pooled Odds ratios (ORs) with 95% confidence intervals
(CIs) were used to evaluate the association between
XPD Lys751Gln polymorphism and susceptibility to
HNC on the basis of the distinct genotype and allele fre-
quencies of XPD Lys751Gln polymorphism in two
groups. The five distinct genetic models comprised allele
contrast (Gln v Lys), homozygous comparison (Gln/Gln
v Lys/Lys), heterozygous comparison (Lys/Gln v Lys/
Lys), dominant model (Lys/Gln + Gln/Gln v Lys/Lys)
and recessive model (Gln/Gln v Lys/Gln + Lys/Lys). We
used I2 statistic to check heterogeneity. P-value of het-
erogeneity less than 0.1 was confirmed as statistically
significant. The summary ORs were calculated under
fixed effects model in the case that P-value of heterogen-
eity was more than 0.1. Otherwise,we used random ef-
fects model to perform the data calculation. HWE in
controls was assessed by the online program (http://ihg.
gsf.de/cgi-bin/hw/hwa1.pl). Funnel plots,Begg’s test and
Egger’s linear regression method were used to evaluate
publication bias. P < 0.05 was confirmed as statistically
significant to evaluate the data except heterogeneity test.
We conducted subgroup analyses by stratification of eth-
nicity, source of controls and cancer type.In addition,
sensitivity analysis was conducted to verify the impact of
individual study respectively. All the data statistics and
analyses were conducted using Stata version 12.0 (Stata
Corporation, College Station, TX).
Results
Study characteristics
Selection process was summarized by the flow diagram
in Figure 1. In summary, a total of 339 potentially relevant
papers were identified after searching the OVID, Medline,
Embase,Pubmed, Web of Science databases. Two authors
(H. Lin and D. Lin) excluded ineligible articles independ-
ently. Then, 288 including duplicates or not related arti-
cles were excluded during screening. Then, fifty-one
potentially relevant papers on XPD Lys751Gln poly-
morphism and susceptibility to HNC were selected. After
careful examination of these papers, twenty-nine papers
were excluded for the following reasons: seven were re-
views, nine without normal healthy controls, two on can-
cers other than HNC, one was overlapped study, eight on
Figure 1 The flow diagram of included/excluded studies.
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Then, twenty-two potentially appropriate papers reported
the association of XPD Lys751Gln polymorphism with the
risk of HNC. However, three papers [17-19] were excluded
due to the genotype frequencies of control group being in-
consistent with HWE and one paper [20] was ruled out
for the study was focusing on premalignant lesion instead
of cancer. As a result,eighteen eligible studies [21-38] with
a total sample size of 4,510 HNC patients and 6,933 con-
trols were included. In those included studies, eleven stud-
ies [21-26,33-36,38] were performed in Caucasians and
seven [27-32,37] were conducted in Asians. Thirteen stud-
ies [21,22,24,26-28,31,33-38] were hospital-based, three
studies [29,30,32] were population-based and one [25] was
nested case–control study and one study [23] conducted
by Huang et al. was a pooled analysis comprised two
population-based studies and one hospital-based study.
The study conducted by Huang [23] recruited whites,
blacks and others and had overall data of all subjects and
white subjects. However, the genotype frequencies of con-
trols in all subjects were inconsistent with HWE, so we
only included white subjects. Two studies [21,38] was per-
formed on laryngeal cancer, three studies [27,31,37] on
oral cancer, one [29] on nasopharyngeal cancer and twelve
studies [22-26,28,30,32-36] on head and neck cancers. We
only included six studies [21,27,29,31,37,38] having de-
tailed genotype data of laryngeal cancer, oral cancer and
nasopharyngeal cancer for subgroup analysis by cancertype. Consequently, we performed subgroup analysis by
stratification of ethnicity, source of controls and cancer
type. Details of subjects in these studies were outlined in
Table 1.
Association between XPD Lys751Gln polymorphism and
susceptibility to HNC
The main results of our meta-analysis under five distinct
genetic models were listed in Table 2. Overall, XPD Lys
751Gln polymorphism had no association with increased
HNC risk under all five genetic models (allele contrast:
OR = 1.05, 95% CI = 0.95-1.18, P = 0.337, Figure 2;
homozygous comparison: OR = 1.18, 95% CI = 0.96-
1.45, P = 0.118; heterozygous comparison: OR = 1.02,
95% CI = 0.90-1.17, P = 0.725; dominant model: OR =1.05,
95% CI =0.91-1.21; P = 0.538; recessive model: OR = 1.11,
95% CI = 0.98-1.26, P = 0.112).
In the subgroup analysis by ethnicity and source of con-
trols, still no significant association was found (Figure 2,
Table 2).
In the subgroup analysis by cancer type, XPD Lys7
51Gln polymorphism had statistically significant associ-
ation with elevated laryngeal cancer (LC) and nasopharyn-
geal cancer (NPC) risk under heterozygous comparison
and dominant model (P < 0.05, Figure 3, Table 2) and bor-
derline significantly increased risk was found under allele
contrast for LC (OR =0.82, 95% CI = 0.67-1.00, P = 0.056)
and NPC (OR =0.60, 95% CI =0.36-1.00, P = 0.05).
Table 1 Characteristics of included studies


















Sturgis [26] 2000 America Caucasian HB PCR-RFLP SCCHN 189 496 75 83 31 218 221 57 0.9304
Gajecka [21] 2005 Poland Caucasian HB PCR-RFLP LC 293 320 110 135 48 87 175 58 0.0659
Huang [23] 2005 America Caucasian Mix* TaqMan-PCR HNC 425 683 176 188 61 296 292 95 0.0951
Rydzanicz [24] 2005 Poland Caucasian HB PCR-RFLP HNC 172 143 69 73 30 54 64 25 0.4265
Kietthubthew
[32]
2006 Thailand Asian PB PCR-RFLP SCCOC 105 164 83 21 1 126 36 2 0.7489
Matullo [25] 2006 Europe Caucasian nest TaqMan-PCR UADC 82 1094 34 39 9 397 504 193 0.1330
Ramachandran
[37]
2006 India Asian HB PCR-RFLP OC 110 110 49 46 15 71 31 8 0.0908
An [22] 2007 America Caucasian HB PCR-RFLP SCCHN 829 854 330 394 105 358 386 110 0.7091
Bau [27] 2007 Taiwan Asian HB PCR-RFLP OC 154 105 134 18 2 89 15 1 0.6824
Yang [29] 2007 China Asian PB PCR-RFLP NPC 153 168 128 24 1 124 43 1 0.1805
Majumder [31] 2007 India Asian HB PCR-RFLP OC 309 388 158 125 26 190 158 40 0.4030
Harth [35] 2008 Germany Caucasian HB PCR-RFLP SCCHN 312 300 111 154 47 108 149 43 0.4642
Mitra [34] 2009 North
India
Caucasian HB PCR-RFLP SCCHN 275 385 88 148 39 163 179 43 0.5571
Jelonek [33] 2010 Poland Caucasian HB PCR-RFLP HNC 103 110 29 52 22 38 60 12 0.1030
Ji [28] 2010 Korea Asian HB PCR-SBE SCCHN 267 348 232 32 3 298 48 2 0.9645
Stembalska [38] 2011 Poland Caucasian HB PCR-RFLP LSCC 60 100 20 26 14 32 46 22 0.4795
Kumar [36] 2012 North
India
Caucasian HB PCR-RFLP SCCHN 278 278 92 125 61 129 110 39 0.0531
Yuan [30] 2012 China Asian PB TaqMan-PCR HNC 394 887 333 57 4 752 129 6 0.8556
HB hospital-based study, PB population-based study, *two population-based studies and one hospital-based study, nest nested case–control study, PCR-RFLP poly-
merase chain reaction-restriction fragment length polymorphism, PCR-SBE polymerase chain reaction-single base extension, HNC head and neck cancer, SCCHN
squamous cell cancer of the head and neck, NPC nasopharyngeal cancer, LC laryngeal cancer, LSCC laryngeal squamous cell cancer, UADC upper aerodigestive
tract cancer, OC oral cance, HWE Hardy–Weinberg equilibrium.
Table 2 Main results of pooled ORs in this meta-analysis
Study groups n Gln v Lys Gln/Gln v Lys/Lys Lys/Gln v Lys/Lys Lys/Gln + Gln/Gln v
Lys/Lys
Gln/Gln v Lys/Lys +
Lys/Gln
OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph
All 18 1.05(0.95–1.18) <0.001 1.18(0.96–1.45) 0.030 1.02(0.90–1.17) 0.011 1.05(0.91–1.21) 0.001 1.11(0.98–1.26) 0.359
Ethnicity 18
Caucasian 11 1.08(0.96–1.23) 0.002 1.17(0.92–1.49) 0.008 1.06(0.91–1.25) 0.033 1.09(0.92–1.29) 0.004 1.11(0.97–1.27) 0.150
Asian 7 0.99(0.78–1.26) 0.026 1.13(0.75–1.70) 0.437 0.95(0.73–1.23) 0.062 0.97(0.74–1.27) 0.028 1.09(0.74–1.60) 0.687
Source
HB 13 1.11(0.98–1.27) 0.001 1.26(0.98–1.61) 0.014 1.07(0.91–1.27) 0.009 1.11(0.93–1.33) 0.001 1.16(1.00–1.33) 0.273
Mix 1 1.05(0.88–1.26) – 1.08(0.74–1.57) – 1.08(0.83–1.41) – 1.08(0.85–1.38) – 1.04(0.73–1.47) –
PB 3 0.86(0.62–1.19) 0.193 1.25(0.44–3.54) 0.870 0.82(0.57–1.18) 0.181 0.83(0.57–1.19) 0.168 1.26(0.45–3.57) 0.888
nest 1 0.78(0.56–1.08) – 0.54(0.26–1.16) – 0.90(0.56–1.46) – 0.80(0.51–1.27) – 0.58 (0.28–1.17) –
Cancer type 6 0.95(0.72–1.25) 0.005 0.88(0.65–1.18) 0.185 0.87(0.60–1.27) 0.007 0.90(0.61–1.31) 0.002 0.97(0.73–1.28) 0.640
LC 2 0.72(0.48–1.10) 0.339 0.72(0.48–1.10) 0.383 0.66(0.48–0.91) 0.347 0.69(0.48–0.97) 0.285 0.93(0.64–1.34) 0.655
OC 3 1.16(0.68–1.98) 0.007 1.08(0.69–1.69) 0.075 1.18(0.67–2.05) 0.036 1.20(0.65–2.21) 0.012 1.02(0.66–1.58) 0.213
NPC 1 0.60(0.36–1.00) – 0.97(0.06–15.66) – 0.54(0.31–0.94) – 0.55(0.32–0.95) – 1.10(0.07–17.72) –
Ph P-value of Q-test for heterogeneity test, HB hospital-based study, PB population-based study, nest nested case–control study, LC laryngeal cancer, OC oral
cancer, NPC nasopharyngeal cancer.
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Figure 2 Forest plot of XPD Lys751Gln polymorphism associated with HNC risk by ethnicity stratification under allele contrast
(Gln v Lys). Random effects model was used.
Figure 3 Forest plot of XPD Lys751Gln polymorphism associated with HNC risk by cancer type stratification under heterozygous
comparison (Lys/Gln v Lys/Lys). Random effects model was used.
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Figure 4 Begg’s funnel plot with pseudo-95% confidence limits under allele contrast (Gln v Lys). Each small circle represents a separate
study for the indicated association.
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likely to have LC or NPC.
Heterogeneity and publication bias
There were no significant heterogeneities for the overall
analysis under recessive model and the subgroup analysis
by cancer type under homozygous comparison and reces-
sive model (Ph>0.10, Table 2), so the results were assessed
under fixed effects model. However, there were some sig-
nificant heterogeneities for the overall analysis under allele
contrast, homozygous comparison, heterozygous compari-
son and dominant model and the subgroup analysis by can-
cer type under allele contrast, heterozygous comparisonFigure 5 The result of sensitive analysis under allele contrast (Gln v L
summary OR. The middle vertical axis indicates the overall OR, and the two
from the meta-analysis. The two ends of the dotted lines represent the 95%and dominant model (Ph<0.10, Table 2). Hence, the re-
sults were assessed under random effects model.
In this meta-analysis, we used both funnel plots, Begg’s
test and Egger’s linear regression method to evaluate the
publication bias. There were no obvious asymmetry in
the funnel plots. Meanwhile, results of Begg’s test and
Eggers’s linear regression method indicated that there
were no obvious publication bias (P > 0.05, Figure 4).
Sensitivity analysis
Sensitivity analysis was performed to reflect the impact of
the individual study to the summarized ORs by removing
one study each time involved in the meta-analysis.ys). This figure shows the influence of individual studies on the
vertical axes indicate the pooled OR when the left study is omitted
CI.
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all genetic models were not significantly altered after sensi-
tivity analysis (Figure 5), indicating that our results were
stable and statistically robust.
Discussion
It has been shown that XPD acting as a key DNA repair
protein in the NER pathway is involved in the pathogenesis
of cancer and XPD Lys751Gln polymorphism may be
involved in the mechanism of carcinogenesis b [39]. To
date, different studies on the association between XPD
Lys751Gln polymorphism and HNC risk have showed
discrepant results. Thus, our meta-analysis from eight-
een studies comprising 4,510 HNC patients and 6,933
controls was performed to precisely assess the possible
association of XPD Lys751Gln polymorphism with the
susceptibility to develop HNC.
Our meta-analysis, which comprised 4,510 HNC patients
and 6,933 controls, indicated the following descriptions:
first, XPD Lys751Gln polymorphism had no association
with increased HNC risk under all five genetic models by
overall analysis; second, still no significant association was
found under five genetic models in the subgroup analysis
by ethnicity and source of controls;third, XPD Lys751Gln
polymorphism had statistically significant association with
elevated LC and NPC risk under heterozygous comparison
and dominant model and borderline significantly increased
risk was found under allele contrast for LC and NPC. The
Lys allele and Lys/Lys genotype of XPD Lys751Gln poly-
morphism may be a risk factor for LC and NPC.
Some limitations of our study should be interpreted.
First, the included studies were carried out mainly in
Caucasians and Asians and only three studies were
population-based, which increased the limitation of statis-
tical power. Hence, studies with larger sample sizes and
representative population should be warranted to verify
our findings. Second, we only included published papers,
as a result, there may be publication bias across studies, al-
though Begg’s test, Egger’s linear regression method did
not show any conspicuous publication bias. Finally, our
results were grounded on unadjusted estimates, however,
XPD Lys751Gln polymorphism is only one phenotype of
HNC and HNC is an intricate disorder, and there are
many other factors comprising genes, occupation, lifestyle,
gender, a history of smoking or drinking, obesity and en-
vironmental factors participating in the development of
HNC. If the individual data including confounding factors
mentioned above were available, a more precise analysis
allowing for the adjustment by other covariants should be
performed in the future.
Conclusion
In conclusion, there is overall lack of association between
XPD Lys751Gln polymorphism and HNC risk under allfive genetic models and still no significant association was
found in the subgroup analysis by ethnicity and source of
controls. However, XPD Lys751Gln polymorphism was
significantly associated with susceptibility to LC and NPC.
Carriers of Lys allele and Lys/Lys genotype may be asso-
ciated with elevated LC and NPC risk. The Lys allele and
Lys/Lys genotype of XPD Lys751Gln polymorphism may
be a risk factor for LC and NPC. However, relatively
modest sample sizes were included in this meta-analysis
and studies with large sample sizes and representative
population are warranted to further clarify this finding.
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